Nyon, Switzerland
Nuvamid, founded in 2019 and headquartered in Switzerland, is a clinical stage biotech with a focus on the research and utilization of nucleotides as therapeutics for rare diseases. Known for their slogan, "A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases," their expertise lies particularly in targeting rare blood disorders.
The company has built a robust collaborative framework, leveraging partnerships with leading institutions such as Lausanne University in Switzerland, EFS, INSERM, and CNRS in France, and the Buck Institute in the USA. This collaboration has enabled them to deepen their understanding of blood cell disorders and NAD metabolism's role in age-related disease pathologies.
Their flagship molecule, NUV01, is currently undergoing evaluation in three Phase 2 trials, demonstrating their progress in bringing innovative therapeutics to market. Although no recent investments have been disclosed, Nuvamid's strategic focus and research pipeline position it as a compelling candidate for venture capital interest within the Health Care, Manufacturing, and Pharmaceutical industries.
